A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Registration Number
- NCT00326092
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to assess the comfort of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
- Adults of either sex and any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)
Exclusion Criteria
- Under 18
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Ocular discomfort
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of Alcon Research's glaucoma therapy in open-angle glaucoma and ocular hypertension?
How does the Alcon Research glaucoma therapy compare to standard-of-care treatments like beta-blockers and prostaglandin analogs in terms of effectiveness and patient comfort?
Are there specific biomarkers, such as intraocular pressure or optic nerve head parameters, that predict response to the glaucoma therapy in NCT00326092?
What are the known or potential adverse events associated with the Alcon Research glaucoma therapy and how can they be managed in clinical practice?
What related compounds or combination approaches are being explored by Alcon Research or competitors for treating open-angle glaucoma and ocular hypertension?
Trial Locations
- Locations (1)
Fort Worth and Other Sites
🇺🇸Fort Worth, Texas, United States
Fort Worth and Other Sites🇺🇸Fort Worth, Texas, United States